Asio Capital, LLC Vertex Pharmaceuticals Inc Transaction History

Asio Capital, LLC

$507 Million
Q3 2024

A detailed history of Asio Capital, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Asio Capital, LLC holds 11,128 shares of VRTX stock, worth $5.59 Million. This represents 1.02% of its overall portfolio holdings.

Number of Shares

11,128

Previous 11,161 0.3%

Holding current value

$5.59 Million

Previous $5.23 Million 1.07%

% of portfolio

1.02%

Previous 1.1%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 10, 2024	SELL	$460.0 - $505.78 $15,180 - $16,690	-33 Reduced 0.3%	11,128 $5.18 Million
Q2 2024 Jul 17, 2024	BUY	$392.81 - $485.53 $92,703 - $114,585	236 Added 2.16%	11,161 $5.23 Million
Q1 2024 Apr 16, 2024	SELL	$407.69 - $446.08 $7,746 - $8,475	-19 Reduced 0.17%	10,925 $4.57 Million
Q4 2023 Jan 11, 2024	SELL	$343.0 - $410.68 $277,830 - $332,650	-810 Reduced 6.89%	10,944 $4.45 Million
Q3 2023 Oct 31, 2023	SELL	$338.18 - $362.46 $32,127 - $34,433	-95 Reduced 0.8%	11,754 $4.09 Million
Q2 2023 Aug 03, 2023	SELL	$314.42 - $351.91 $31,127 - $34,839	-99 Reduced 0.83%	11,849 $4.17 Million
Q1 2023 Apr 24, 2023	SELL	$283.23 - $323.1 $10,479 - $11,954	-37 Reduced 0.31%	11,948 $3.76 Million
Q4 2022 Jan 27, 2023	SELL	$285.76 - $321.48 $21,717 - $24,432	-76 Reduced 0.63%	11,985 $0
Q3 2022 Oct 27, 2022	BUY	$273.83 - $305.53 $128,152 - $142,988	468 Added 4.04%	12,061 $3.49 Million
Q2 2022 Aug 04, 2022	BUY	$234.96 - $292.55 $81,531 - $101,514	347 Added 3.09%	11,593 $3.27 Million
Q1 2022 Apr 28, 2022	BUY	$221.42 - $260.97 $2.49 Million - $2.93 Million	11,246 New	11,246 $2.94 Million

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Asio Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Asio Capital, LLC with notifications on news.

Account